BioSpace News Archive

Today, findings from the ongoing clinical trial of VX-880, a phase 1/2, multi-center, single-arm, open-label study in patients with type 1 diabetes (T1D) were presented, demonstrating the potential of stem cell-derived islet cell therapy as a future treatment option for patients with T1D.

XORTX Therapeutics Inc. would like to remind shareholders that they have until 10:00 a.m. on Monday, June 26, 2023 to vote their shares for the Company’s upcoming annual and special meeting of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m.

Carmot Therapeutics, Inc. announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants and a preclinical study in rodent models of type 1 diabetes to support the effects of CT-868 as an adjunct to insulin treatment.

Findings from two studies showcase groundbreaking technology and the latest diabetes developments related to glucose control and diabetic retinopathy.

Akero Therapeutics, Inc. announced two presentations of secondary and post-hoc analyses of the Phase 2b HARMONY study of efruxifermin in patients with pre-cirrhotic nonalcoholic steatohepatitis, fibrosis stage 2 or 3.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST) today announced financial and operational results for the fiscal year ended March 31, 2023.

Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities.

Aldeyra today announced that it will be added to the Russell 2000® and the Russell 3000® indexes, effective after the U.S. equity markets close on June 23, 2023.

Appili Therapeutics Inc. today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.

Bicycle Therapeutics plc today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th.